Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Allergan cautions against exchange as Valeant gets down to the 'facts'

23.06.2014 / Fierce Pharma

Allergan's board has already rejected Valeant's $53 billion buyout bid, prompting the wannabe-acquirer to take the proposal directly to shareholders. Unsurprisingly enough, Allergan's board doesn't like that too much, either. And if you ask Valeant, it's twisting the facts to get shareholders on its side.

Cover_HCLS_GREECE LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: